ZyVersa reports Q3 net loss of $19.8M; cash only $0.5M, going concern risk

ZyVersa Therapeutics, Inc.

2025-Q3 EPS reported -$4.63

Cash on hand $0.5M as of Sept 30, 2025; expects month-to-month liquidity only, needs additional financing.
Net loss $19.8M vs $2.4M in Q3 2024, driven by $18.6M impairment of in-process R&D due to market cap decline.
Pre-tax loss $20.7M; R&D expense $0.4M (-16.3% YoY), G&A $1.7M (-5.1% YoY).
Raised $2.05M in Q3 2025, $4.05M YTD; company flags need for equity/debt or collaboration funding.
Lead programs: VAR 200 for FSGS (kidney) and IC 100 for cardiometabolic diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.